Abstract: A method of treating Parkinson's Disease, Huntington's Disease and the like, diseases with abnormal dopamine-neurotransmission, using small molecules administered systemically that penetrate into the central nervous system to inhibit the rate-limiting step of dopamine synthesis in the central nervous system, the conversion of L-tyrosine to L-3, 4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase along with its cofactors tetrahydrobiopterin and iron (Fe+).

Abstract: A method of treating Parkinson's Disease, Huntington's Disease and the like, diseases with abnormal dopamine-neuro-transmission, using small molecules administered systemically that penetrate into the central nervous system to inhibit the rate-limiting step of dopamine synthesis in the central nervous system, the conversion of L-tyrosine to L-3, 4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase along with its cofactors tetrahydrobiopterin and iron (Fe+).

Abstract: Nocilytic devices and methods for treatment of dyspareunia are provided. In particular, a device is provided, which inserts intravaginally with inflatable balloons to map the location of pain during application of force exerted against/on the luminal side of the vaginal wall and/or vulva of a human patient, or sensors to detect locations for application of nocilytic therapy.

Abstract: A method of treating Parkinson's Disease, Huntington's Disease and the like, diseases with abnormal dopamine-neuro-transmission, using small molecules administered systemically that penetrate into the central nervous system to inhibit the rate-limiting step of dopamine synthesis in the central nervous system, the conversion of L-tyrosine to L-3, 4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase along with its cofactors tetrahydrobiopterin and iron (Fe+).

Abstract: The described invention provides cellular therapeutic approaches for treating a vascular insufficiency following a traumatic injury to head or spine that results in an injury to brain, spinal cord, or both by administering a therapeutic amount of an isolated, nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+ cells, which further contains a subpopulation of potent SDF-1 mobile CD34+/CXCR-4 cells that have CXCR-4-mediated chemotactic activity.

Abstract: A system and method are described to identify risks and assess the efficacy and safety associated with drug, biologic, nutritional, medical food and medical device therapies throughout the treatment development process. The data measured are evaluated in relation to a patient's specific physiologic state (for example, data collected throughout a biological cycle) to determine the attribution to specific organ systems, functions or mechanisms, and are reported within this context. Further, the system and method enable real time access and entry of patient data stored in a centralized database via the internet or other computing device.